Infants have the highest incidence of atopic dermatitis (AD) in the United States, but the fewest treatment options. This is a case a doctor submitted about a baby who is refractory to multiple oral and topical treatments. A multidisciplinary panel discusses how they would approach the baby’s treatment, emerging options for this vulnerable patient population, and if anything can be done now to prevent progression of the atopic march later.
The target audience for this activity is US-based dermatologists, allergists, and immunologists, as well as NPs and PAs that diagnose and manage atopic dermatitis (AD). Primary care clinicians will also be included as a secondary audience.
Educational Objectives
Upon completion of this activity, participants should be better able to:
Apply current principles of pathophysiology of atopic dermatitis (AD) and the concept of atopic march to therapeutic approaches to disease management
Develop treatment plans for patients with AD that reflect evidence-based guidelines, use of new and emerging therapeutic options, assessment of treatment response, and strategies to optimize short-term control and long-term management of the disease
Assess for and manage quality-of-life issues and psychosocial comorbidities in patients with AD
Utilize shared decision making and develop treatment plans that will result in high levels of adherence and better patient outcomes
Activity Faculty
Peter A. Lio, MD (Chair)
Assistant Professor, Clinical Dermatology and Pediatrics
Northwestern University
Feinberg School of Medicine
Ann & Robert H. Lurie Children’s Hospital
Chicago, IL
Mark Boguniewicz, MD
Professor, Division of Allergy-Immunology
Department of Pediatrics
National Jewish Health and University of Colorado School of Medicine
Denver, CO
Eric L. Simpson, MD, MCR
Professor, Dermatology Director, Clinical Research
Department of Dermatology
Oregon Health & Science University
Portland, OR